Cell populations which co-express CD49c and CD90
First Claim
1. A substantially homogenous cell population which co-expresses CD49c, CD90 and at least one cardiac-related transcription factor.
3 Assignments
0 Petitions
Accused Products
Abstract
Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are made by selecting from a cultured source of a cell population which co-express CD49c and CD90 and modifying the cell population. The committed progenitor cells can be employed to treat a human suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition and to formulate pharmaceutical compositions. In a further embodiment, a substantially homogenous populaton of cells which co-express CD49c, CD90 and at least one cardiac-related transcription factor is made and can be used to treat a human suffering from a cardiac condition.
223 Citations
60 Claims
- 1. A substantially homogenous cell population which co-expresses CD49c, CD90 and at least one cardiac-related transcription factor.
- 8. A substantially homogenous cell population which co-expresses CD49c, CD90, and at least one cardiac-related transcription factor, but does not express bone sialoprotein.
-
10. A substantially homogenous cell population which co-expresses CD49c, CD90, GATA4, Irx4 and Nkx2.5.
-
11. A substantially homogenous cell population which co-expresses CD49c, CD90, telomerase, GATA4, Irx4 and Nkx2.5.
-
12. A method of making a substantially homogenous cell population which co-expresses CD49c, CD90 and at least one cardiac-related transcription factor, comprising the steps of:
-
a) culturing a source of the cell population under a low oxygen condition; and
b) treating the cultured source of the cell population with a protein kinase C inhibitor and a DNA methylation inhibitor. - View Dependent Claims (13, 14, 15, 16)
-
-
17. A method of making a substantially homogenous cell population which co-expresses CD49c, CD90, telomerase and at least one cardiac-related transcription factor, comprising the steps of:
-
a) culturing a source of the cell population under a low oxygen condition; and
b) treating the cultured source of the cell population with a protein kinase C inhibitor and a DNA methylation inhibitor.
-
-
18. A method of making a substantially homogenous cell population which co-expresses CD49c, CD90, telomerase, GATA4, Irx4 and Nkx2.5, comprising the steps of:
-
a) culturing a source of the cell population under a low oxygen condition; and
b) treating the cultured source of the cell population with a protein kinase C inhibitor and a DNA methylation inhibitor. - View Dependent Claims (19, 20, 21)
-
-
22. A method of making a substantially homogenous cell population which co-expresses CD49c, CD90, GATA4, Irx4 and Nkx2.5, comprising the steps of:
-
a) culturing a source of the cell population under a low oxygen condition; and
b) treating the cultured source of the cell population with a protein kinase A inhibitor and a DNA methylation inhibitor.
-
-
23. A method of making a substantially homogenous cell population which co-expresses CD49c, CD90 and at least one cardiac-related transcription factor, comprising the step of treating a cell population which co-expresses CD49c and CD90 with a protein kinase C inhibitor and a DNA methylation inhibitor.
-
24. A method of making a substantially homogenous cell population which co-expresses CD49c, CD90, telomerase and at least one cardiac-related transcription factor, comprising the step of treating a cell population which co-expresses CD49c, CD90 and telomerase with a protein kinase C inhibitor and a DNA methylation inhibitor.
-
25. A method of making a substantially homogenous cell population which co-expresses CD49c, CD90, telomerase, GATA4, Irx4 and Nkx2.5, comprising the step of treating a cell population which co-expresses CD49c, CD90 and telomerase with a protein kinase C inhibitor and a DNA methylation inhibitor.
- 26. A method of treating a myocardial infarction in a human, comprising the step of administering a substantially homogenous cell population which co-expresses CD49c, CD90 and at least one cardiac-related transcription factor to the human.
-
28. A method of treating a myocardial infarction in a human comprising the step of administering a substantially homogenous cell population which co-expresses CD49c, CD90 and at least one cardiac-related transcription factor to the human.
-
29. A method of treating a myocardial infarction in a human comprising the step of administering to the human a substantially homogenous cell population which co-expresses CD49c, CD90, GATA4, Irx4 and Nkx2.5.
-
30. A method of treating a myocardial infarction in a human, comprising the step of administering to the human a substantially homogenous cell population which co-expresses CD49c, CD90, telomerase, GATA4, Irx4 and Nkx2.5.
-
31. A method of treating a myocardial infarction in a human, comprising the steps of:
-
a) culturing a source of a cell population under a low oxygen condition;
b) treating the cultured source of the cell population with a protein kinase C inhibitor and a DNA methylation inhibitor; and
d) administering the treated cell population to the human. - View Dependent Claims (32, 33, 34, 35, 36, 37)
-
-
38. A method of treating a myocardial infarction in a human, comprising the steps of:
-
a) treating a cell population which co-expresses CD49c and CD90 with a protein kinase C inhibitor and a DNA methylation inhibitor; and
b) administering the treated cells to the human. - View Dependent Claims (39, 40, 41)
-
-
42. A method of treating a congestive heart failure in a human, comprising the step of administering a substantially homogenous cell population which co-expresses CD49c, CD90 and at least one cardiac-related transcription factor to the human.
-
43. A method of treating a congestive heart failure in a human comprising the step of administering a substantially homogenous cell population which co-expresses CD49c, CD90 and at least one cardiac-related transcription factor to the human.
-
44. A method of treating a congestive heart failure in a human comprising the step of administering a substantially homogenous cell population which co-expresses CD49c, CD90, GATA4, Irx4 and Nkx2.5 to the human.
-
45. A method of treating a congestive heart failure in a human, comprising the step of administering to the human a substantially homogenous cell population which co-expresses CD49c, CD90, telomerase, GATA4, Irx4 and Nkx2.5.
-
46. A method of treating a congestive heart failure in a human, comprising the steps of:
-
a) culturing a source of a cell population under a low oxygen condition;
b) treating the cultured source of the cell population with a protein kinase C inhibitor and a DNA methylation inhibitor; and
d) administering the treated cell population to the human
-
- 47. A method of forming a committed progenitor cell-type, comprising the step of combining a substantially homogenous population of cells that co-expresses CD49c and CD90 with a population of cells that includes at least one committed progenitor cell type.
- 50. A substantially homogenous cell population which co-expresses CD49c, CD90 and has a doubling time of less that about 144 hours when cultured under a low oxygen condition.
-
56. A substantially homogenous cell population which co-expresses CD49c, CD90 and has a doubling time less than about 144 hours when cultured under a low oxygen condition, wherein the substantially homogenous cell population is formed by a method, comprising the step of culturing a cell population source at a seeding density of about 100 cells/cm2 under the low oxygen condition.
-
57. A pharmaceutical composition comprising a substantially homogenous cell population which co-expresses CD49c, CD90 and at least one cardiac-related transcription factor.
-
58. A pharmaceutical composition comprising a substantially homogenous cell population which co-expresses CD49c, CD90, telomerase and at least one cardiac-related transcription factor.
-
59. A pharmaceutical composition comprising a substantially homogenous cell population which co-expresses CD49c, CD90, telomerase, GATA4, Irx4 and Nkx2.5.
-
60. A pharmaceutical composition comprising a substantially homogenous cell population which co-expresses CD49c, CD90, GATA4, Irx4 and Nkx2.5.
Specification